Despite this measured change, clinical questionnaires showed that the response to ADHD medication was maintained throughout the year of treatment, though the authors speculate that the upregulation of dopamine transporters may decrease treatment efficacy and exacerbate symptoms while not under the effects of the medication [14]. This evidence concerns the gene SLC6A3 and attention deficit-hyperactivity disorder.